Abstract: Provided are omecamtiv mecarbil dihydrochloride salt forms, compositions and pharmaceutical formulations thereof, and methods for their preparation and use.

Abstract: The present invention provides new methods for preparing compound 5, and pharmaceutically acceptable salts thereof, of structure Compound 5, or a pharmaceutically acceptable salt thereof, is an important intermediate in the synthesis of carfilzomib. The invention further provides methods of making a useful manganese catalyst that may be used in the epoxidation step of the present invention.

Abstract: Provided herein are free base crystalline forms, crystalline salts, and an amorphous salts of omecamtiv mecarbil.

Abstract: Provided are omecamtiv mecarbil dihydrochloride salt forms, compositions and pharmaceutical formulations thereof, and methods for their preparation and use.

Abstract: The instant disclosure is directed to solution phase fragment coupling methods for preparing etelcalcetide and its pharmaceutically acceptable salts.

Abstract: Provided are omecamtiv mecarbil dihydrochloride salt forms, compositions and pharmaceutical formulations thereof, and methods for their preparation and use.

Abstract: Provided are omecamtiv mecarbil dihydrochloride salt forms, compositions and pharmaceutical formulations thereof, and methods for their preparation and use.

Abstract: A method for preparing AMG 416, or a pharmaceutically acceptable salt thereof, is provided.

Abstract: A method for preparing AMG 416, or a pharmaceutically acceptable salt thereof, is provided. AMG 416 is a synthetic, eight amino-acid selective peptide agonist of the calcium sensing receptor. It is being developed as an intravenous treatment of secondary hyperparathyroidism (SHPT) in hemodialysis patients with chronic kidney disease-mineral and bone disorder (CKD-MBD).

Abstract: Provided are omecamtiv mecarbil dihydrochloride salt forms, compositions and pharmaceutical formulations thereof, and methods for their preparation and use.

Abstract: Provided are omecamtiv mecarbil dihydrochloride salt forms, compositions and pharmaceutical formulations thereof, and methods for their preparation and use.

Abstract: The instant disclosure is directed to solution phase fragment coupling methods for preparing etelcalcetide and its pharmaceutically acceptable salts.

Abstract: Provided is a method for preparing a bulk C—AlN composite aerogel with high strength and high temperature resistance, which includes: evenly stirring aluminum chloride crystals, water, ethanol and epoxy propane, to obtain a clear aluminum oxide sol solution, then adding formaldehyde and resorcinol to the solution and performing even stirring, to obtain an RF/Al2O3 composite aerogel sol solution, leaving the gel to stand, treating the sample by using a supercritical CO2 drying method, and finally heat-treating the sample at a high temperature under the condition of nitrogen, to obtain the bulk C—AlN composite aerogel with high strength and high temperature resistance. The composite aerogel prepared by using this method has advantages of high integrity, high specific surface area, intact structure, low heat conductivity, low density, and high strength.

Abstract: A method for preparing AMG 416, or a pharmaceutically acceptable salt thereof, is provided. AMG 416 is a synthetic, eight amino-acid selective peptide agonist of the calcium sensing receptor. It is being developed as an intravenous treatment of secondary hyperparathyroidism (SHPT) in hemodialysis patients with chronic kidney disease—mineral and bone disorder (CKD-MBD).

Abstract: Provided are omecamtiv mecarbil dihydrochloride salt forms, compositions and pharmaceutical formulations thereof, and methods for their preparation and use.

Abstract: Provided is a method for preparing a bulk C—AlN composite aerogel with high strength and high temperature resistance, which includes: evenly stirring aluminum chloride crystals, water, ethanol and epoxy propane, to obtain a clear aluminum oxide sol solution, then adding formaldehyde and resorcinol to the solution and performing even stirring, to obtain an RF/Al2O3 composite aerogel sol solution, leaving the gel to stand, treating the sample by using a supercritical CO2 drying method, and finally heat-treating the sample at a high temperature under the condition of nitrogen, to obtain the bulk C—AlN composite aerogel with high strength and high temperature resistance. The composite aerogel prepared by using this method has advantages of high integrity, high specific surface area, intact structure, low heat conductivity, low density, and high strength.

Abstract: The present invention relates to an IEEE1588 protocol negative testing method, comprises steps of: connecting a IEEE1588 tester and a slave clock DUT to establish a real-time closed-loop feedback mechanism; taking the IEEE1588 tester as a master clock, and establishing a stable time synchronization with the slave clock DUT; obtaining the timing offset or path delay of the slave clock DUT before disturbance; assembling an abnormal message in a frame and sending it to the slave clock DUT; calculating the timing offset or path delay increment after disturbance of the abnormal message; determining whether there is a sudden change in the timing offset or path delay of the slave clock DUT, wherein if there is no sudden change, the test passes; otherwise the test fails.

Abstract: The invention provides two process for synthesizing substituted aminothiazolone compounds as inhibitors of 11-?-hydroxy steroid dehydrogenase type 1. The processes allow the stereoselective synthesis of the desired compounds without the use of stoichiometric amounts of chiral catalysts.

Abstract: The invention provides two process for synthesizing substituted aminothiazolone compounds as inhibitors of 11-?-hydroxy steroid dehydrogenase type 1. The processes allow the stereoselective synthesis of the desired compounds without the use of stoichiometric amounts of chiral catalysts.

Abstract: The present invention relates to an IEEE1588 protocol negative testing method, comprises steps of: connecting a IEEE1588 tester and a slave clock DUT to establish a real-time closed-loop feedback mechanism; taking the IEEE1588 tester as a master clock, and establishing a stable time synchronization with the slave clock DUT; obtaining the timing offset or path delay of the slave clock DUT before disturbance; assembling an abnormal message in a frame and sending it to the slave clock DUT; calculating the timing offset or path delay increment after disturbance of the abnormal message; determining whether there is a sudden change in the timing offset or path delay of the slave clock DUT, wherein if there is no sudden change, the test passes; otherwise the test fails.